Publications by authors named "J J Griffith"

Megalithism has been repetitively tied to specialised herding economies in Iberia, particularly in the mountainous areas of the Basque Country. Legaire Sur, in the uplands of Álava region, is a recently excavated passage tomb (megalithic monument) that held a minimum number of 25 individuals. This study analysed the carbon, nitrogen, oxygen, and strontium isotope ratios of 18 individuals, in a multi-tissue sampling study (successional tooth enamel sampling, incremental dentine sampling, and bulk bone collagen sampling).

View Article and Find Full Text PDF

Background: How different gender-specific bone mineral density cutpoint T-scores are associated with different hip fragility fracture (FFx) prediction sensitivity has not been well studied. This article presents an updated analysis of hip FFx prediction among older people by a dual-energy X-ray absorptiometry (DXA) measure, using literature results and our own Chinese data.

Methods: We systematically searched literature reports on DXA T-score results measured at the timepoint of a hip FFx.

View Article and Find Full Text PDF

Background: The COVID-19 pandemic has severely affected vulnerable populations, especially individuals living with HIV/AIDS (PLWHA). The convergence of HIV/AIDS and COVID-19 presents unique challenges, exacerbating existing health concerns and magnifying the strain on individuals already grappling with compromised immune systems. This study aimed to investigate the mental well-being repercussions faced by PLWHA co-infected with SARS-CoV-2 in France.

View Article and Find Full Text PDF

Regulatory T cells (Tregs) are increasingly being recognized for their role in promoting tissue repair. In this issue of the JCI, Chen et al. found that Tregs at the site of bone injury contribute to bone repair.

View Article and Find Full Text PDF

Background And Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn's disease (CD).

Methods: Patients with moderately to severely active CD and clinical response to 12-week risankizumab induction were rerandomized to continued therapy or drug withdrawal in the phase 3 FORTIFY maintenance trial. Incidence rates (events/100 person-years) of CD-related hospitalization and surgery, and the composite of both, through 52 weeks of maintenance were compared between patients achieving vs not achieving predefined endoscopic outcomes following induction.

View Article and Find Full Text PDF